Full Coverage

CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

Nov 2, 2009

Story Timeline: 25 days

London, November , 02, 2009 * First evaluation of CureVac's RNActive® vaccine technology in humans * German authorities approve CV9103 for Phase IIa trial Tuebingen (Germany), November 2, 2009. CureVac GmbH, the mRNA vaccine... [read full story]

Add Comment

PRESS RELEASE: CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

finanztreff.de

Nov 2, 2009

First article on this story:

PRESS RELEASE: CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

finanztreff.de

Nov 2, 2009

Selected publications with coverage of this story:

finanztreff.de pr-inside.com

FROM US SOURCES
- SHOW ARTICLES:
- FROM UK SOURCES
- FROM INDIAN SOURCES
- FROM ALL SOURCES

Show articles from all sources

Male Health, Ambulatory Health Care, Cancer by Body Location, Cancer Therapy, Scientific Discoveries, Health Care, Immunotherapy, Cancers, Pharmaceuticals, Vaccines, Prostate Cancer, Medicines & Remedies, Lung Cancer, Medical Research, Germany

NewstinMap

Click to Open NewstinMap —

Visual Navigation

My Newstin

Context

Germany

Intelligent Data Fusion

About Us

Visit our corporate homepage to learn more about our company and products.

CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

PRESS RELEASE: CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

PRESS RELEASE: CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

Related categories

International Editions